domingo, 22 de noviembre de 2026
ATRX loss may guide targeted treatment for aggressive sarcomas
https://www.news-medical.net/news/20261120/ATRX-loss-may-guide-targeted-treatment-for-aggressive-sarcomas.aspx
Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors. The findings identify ATRX loss as both a marker of poor prognosis and a potential therapeutic target.
The study, published in The Journal of Clinical Investigation, was led by Kunal Rai, Ph.D., professor of Genomic Medicine. If validated in future clinical trials, the results suggest ATRX – one of the most commonly mutated genes in sarcoma – could be a potential biomarker to guide treatment selection for patients with soft-tissue sarcomas.
"For many patients with sarcoma, treatment decisions still are not guided by the biology of their tumors," Rai said. "We found that ATRX loss may identify patients who are more likely to benefit from TEAD inhibitors, creating a potential path toward precision medicine for these difficult-to-treat cancers."
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario